OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 167-184
Open Access | Times Cited: 36
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 167-184
Open Access | Times Cited: 36
Showing 26-50 of 36 citing articles:
Regarding Mastorino et al.'s ‘Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients’
Sebastian Yu, James Cheng‐Chung Wei
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 12
Closed Access | Times Cited: 2
Sebastian Yu, James Cheng‐Chung Wei
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 12
Closed Access | Times Cited: 2
Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: A retrospective analysis of German health claims data
Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 12, pp. 1591-1600
Closed Access
Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 12, pp. 1591-1600
Closed Access
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
April W. Armstrong, Ahmed M. Soliman, Paolo Gisondi, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 11, pp. 3071-3081
Open Access
April W. Armstrong, Ahmed M. Soliman, Paolo Gisondi, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 11, pp. 3071-3081
Open Access
Terapia direcionada para doenças imunomediadas da pele. O que o dermatologista deve saber?
Edinson López, Raúl Cabrera, Cristóbal Lecaros
(2024) Vol. 99, Iss. 4, pp. 546-567
Open Access
Edinson López, Raúl Cabrera, Cristóbal Lecaros
(2024) Vol. 99, Iss. 4, pp. 546-567
Open Access
The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
Nanna Nyholm, Anne Danø, Henrik Schnack, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 607-619
Open Access | Times Cited: 1
Nanna Nyholm, Anne Danø, Henrik Schnack, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 607-619
Open Access | Times Cited: 1
Longitudinal Change in CDC42 in Psoriasis: Correlation with dIsease Activity and Treatment Response
Bing Xu, Leiqiang Fan, Qiaoli Liu, et al.
Biomarkers in Medicine (2023) Vol. 17, Iss. 16, pp. 657-666
Open Access | Times Cited: 1
Bing Xu, Leiqiang Fan, Qiaoli Liu, et al.
Biomarkers in Medicine (2023) Vol. 17, Iss. 16, pp. 657-666
Open Access | Times Cited: 1
Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation.
Matthew Bruno, Bruce Strober, J.Q. Del Rosso
PubMed (2023) Vol. 16, Iss. 9 Suppl 1, pp. S3-S12
Closed Access | Times Cited: 1
Matthew Bruno, Bruce Strober, J.Q. Del Rosso
PubMed (2023) Vol. 16, Iss. 9 Suppl 1, pp. S3-S12
Closed Access | Times Cited: 1
On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 7, pp. 2963-2974
Closed Access | Times Cited: 2
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 7, pp. 2963-2974
Closed Access | Times Cited: 2
Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
Dan Pettitt, Michael Plotnick, Joshua J. Gagne
Dermatology and Therapy (2022) Vol. 12, Iss. 12, pp. 2863-2866
Open Access | Times Cited: 1
Dan Pettitt, Michael Plotnick, Joshua J. Gagne
Dermatology and Therapy (2022) Vol. 12, Iss. 12, pp. 2863-2866
Open Access | Times Cited: 1
Generation and characterization of QLS22001, a humanized monoclonal antibody that neutralizes IL-17A and IL-17F with an extended half-life
Huimin Ma, Wei Zhang, Ke Liu, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109947-109947
Open Access
Huimin Ma, Wei Zhang, Ke Liu, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109947-109947
Open Access
Psoriasis treatment: no more room on the summit?
L. Puig
British Journal of Dermatology (2022) Vol. 187, Iss. 6, pp. 837-837
Closed Access
L. Puig
British Journal of Dermatology (2022) Vol. 187, Iss. 6, pp. 837-837
Closed Access
A Response to: Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 12, pp. 2867-2870
Open Access
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 12, pp. 2867-2870
Open Access
